Identification of potential driver genes in human liver carcinoma by genomewide screening

Cancer Research

Volumn 69, Issue 9, 2009, Pages 4059-4066

  Woo, Hyun Goo ^a   Park, Eun Sung ^b   Lee, Ju Seog ^b   Lee, Yun Han ^a   Ishikawa, Tsuyoshi ^a   Kim, Yoon Jun ^c   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DNA DETERMINATION; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN CELL; LIVER CARCINOMA; LIVER CELL CARCINOMA; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; COMPARATIVE GENOMIC HYBRIDIZATION; DNA, NEOPLASM; GENE DOSAGE; GENOME, HUMAN; HUMANS; LIVER NEOPLASMS; PROGNOSIS; TRANSCRIPTION, GENETIC;

EID: 65949098918     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0164     Document Type: Article

References (39)

1. Lee JS. Chu IS. Heo J. et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-76.
2. Wurmbach E. Chen YB. Khitrov G. et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-47.
3. Ye QH. Qin LX. Forgues M. et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9: 416-23.
4. Lee JS. Heo J. Libbrecht L. et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.
5. Paris PL. Andaya A. Fridlyand J. et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004; 13: 1303-13.
6. Carrasco DR. Tonon G. Huang Y. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313-25.
7. Poon TC. Wong N. Lai PB. Rattray M. Johnson PJ. Sung JJ. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006; 131: 1262-70.
8. Katoh H. Ojima H. Kokubu A. et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology 2007; 133: 1475-86.
9. Pollack JR. Sorlie T. Perou CM. et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002; 99: 12963-8.
10. Patil MA. Chua MS. Pan KH. et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005; 24: 3737-47.
11. Lee SA. Ho C. Roy R. et al. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology 2008; 47: 1200-10.
12. Chiang DY. Villanueva A. Hoshida Y. et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779-88.
13. Stransky N. Vallot C. Reyal F. et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006; 38: 1386-96.
14. de Hoon MJ. Imoto S. Nolan J. Miyano S. Open source clustering software. Bioinformatics 2004; 20: 1453-4.
15. Buzzai M. Jones RG. Amaravadi RK. et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-52.
16. Lamb J. Crawford ED. Peck D. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-35.
17. Su WH. Chao CC. Yeh SH. et al. HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res 2007; 35: D727-31.
18. Thorgeirsson SS. Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
19. Moinzadeh P. Breuhahn K. Stutzer H. Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Br J Cancer 2005; 92: 935-41.
20. Adler AS. Lin M. Horlings H. Nuyten DS. van de Vijver MJ. Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 2006; 38: 421-30.
21. Haiman CA. Patterson N. Freedman ML. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39: 638-44.
22. Woo HG. Park ES. Cheon JH. et al. Gene expressionbased recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 2056-64.
23. Guertin DA. Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
24. Bianco R. Garofalo S. Rosa R. et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 98: 923-30.
25. Fitzgerald JB. Schoeberl B. Nielsen UB. Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006; 2: 458-66.
26. Chan SM. Weng AP. Tibshirani R. Aster JC. Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007; 110: 278-86.
27. Kamei Y. Kito K. Takeuchi T. et al. Human scribble accumulates in colorectal neoplasia in association with an altered distribution of β-catenin. Hum Pathol 2007; 38: 1273-81.
28. Dai C. Whitesell L. Rogers AB. Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007; 130: 1005-18.
29. Hieronymus H. Lamb J. Ross KN. et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10: 321-30.
30. Wei G. Twomey D. Lamb J. et al. Gene expressionbased chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-42.
31. Lee HK. Hsu AK. Sajdak J. Qin J. Pavlidis P. Coexpression analysis of human genes across many microarray data sets. Genome Res 2004; 14: 1085-94.
32. Sahin F. Kannangai R. Adegbola O. Wang J. Su G. Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-5.
33. Parent R. Kolippakkam D. Booth G. Beretta L. Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth. Cancer Res 2007; 67: 4337-45.
34. Villanueva A. Chiang DY. Newell P. et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-83.
35. Philip PA. Mahoney MR. Allmer C. et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-63.
36. Thomas MB. Chadha R. Glover K. et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-67.
37. Zakikhani M. Dowling R. Fantus IG. Sonenberg N. Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-73.
38. Ben Sahra I. Laurent K. Loubat A. et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-86.
39. O'Callaghan-Sunol C. Sherman MY. Heat shock transcription factor (HSF1) plays a critical role in cell migration via maintaining MAP kinase signaling. Cell Cycle 2006; 5: 1431-7.